Quick Answer
Tevogen Bio Holdings Inc. reported Operating Income of -$26.14 million for fiscal year 2025.
Tevogen Bio Holdings Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.14M | +51.2% |
| 2024 | -$53.56M | -505.7% |
| 2023 | -$8.84M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.73M | +5.9% | -5.2% |
| June 30, 2025 | -$5.44M | +36.7% | +47.4% |
| March 31, 2025 | -$10.36M | +64.9% | -70.2% |
| September 30, 2024 | -$6.09M | -161.7% | +29.2% |
| June 30, 2024 | -$8.60M | -293.6% | +70.9% |
| March 31, 2024 | -$29.52M | -1169.9% | -1169.5% |
| September 30, 2023 | -$2.33M | — | -6.4% |
| June 30, 2023 | -$2.18M | — | +6.0% |
- Tevogen Bio Holdings Inc. showed an increase of +51.2% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Tevogen Bio Holdings Inc.’s operating income has declined by 195.6% (from -$8.84 million to -$26.14 million).
- The most recent figure is from Tevogen Bio Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: